Sinopharm Group Co. Ltd. (SHTDY)
Chart Events
Performance Outlook
| Previous Close | 11.23 |
| Open | 11.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 11.14 - 11.22 |
| 52 Week Range | 10.05 - 14.65 |
| Volume | |
| Avg. Volume | 21,401 |
| Market Cap | 7.019B |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | 6.06 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.59 (5.25%) |
| Ex-Dividend Date | Jun 24, 2022 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SHTDY
Related Research
- SINOPHARM GROUP CO. LTD. UNSP AAnalyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.RatingFair ValueEconomic Moat10 days agoMorningstar
- Reuters
INSIGHT-Refugees lack COVID shots because drugmakers fear lawsuits - documents
Tens of millions of migrants may be denied COVID-19 vaccines from a global programme because some major manufacturers are worried about legal risks from harmful side effects, according to officials and internal documents from Gavi, the charity operating the programme, reviewed by Reuters. The legal concerns are an additional hurdle for public health officials tackling the coronavirus – even as officials say unvaccinated people offer an ideal environment for it to mutate into new variants that threaten hard-won immunity around the world. Many COVID-19 vaccine manufacturers have required that countries indemnify them for any adverse events suffered by individuals as a result of the vaccines, the United Nations says.
- Bloomberg
China Vaccine Diplomacy Wavers as Nations Seek Western Shots
(Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the
